Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.40 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | YES1 | P07947 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199272 | 0.81 | STAT3 (0.59) | MALT1STAT3ESR2ESR1MAOA | |
| Lantalucratin B SCHEMBL3092160 | 0.75 | MAOA (0.41) | STAT3MAOAMAOBIDO1KDM4E | |
| SCHEMBL29135713 | 0.75 | STAT3 (0.53) | MALT1STAT3ESR2ESR1MAOA | |
| Dehydroiso-Alpha-Lapachone SCHEMBL29833186 | 0.73 | IDO1 (0.40) | MALT1IDO1KDM4EALDH1A1LMNA | |
| Lantalucratin A SCHEMBL3080844 | 0.70 | TCF4 (0.46) | IDO1KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL23111390 | 0.65 | ESR2 (0.80) | ESR2ESR1MAOAMAOBUGT1A1 | |
| SCHEMBL14439372 | 0.65 | MALT1 (0.90) | MALT1ESR2ESR1MAOAMAOB | |
| SCHEMBL6052899 | 0.63 | NQO1 (0.67) | MALT1ESR2ESR1MAOAMAOB | |
| SCHEMBL8899837 | 0.63 | ESR2 (0.47) | MALT1ESR2ESR1MAOAMAOB | |
| SCHEMBL30003325 | 0.62 | ESR2 (0.74) | ESR2ESR1MAOAMAOBUGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041849-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2024-02-08 | — | — | US | disclosed |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-04-28 | — | — | US | disclosed |
| EP-2532390-B1 | Pharmaceutical composition for liver diseases. | MD BIOALPHA CO LTD (KR) | 2016-08-17 | — | — | EP | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| CN-101679335-B | Novel phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome | MAZENCE INC | 2014-07-30 | — | — | CN | disclosed |
| EP-2137175-B1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC (KR) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | KT & G CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| EP-1848432-B1 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO LTD (KR) | 2013-07-17 | — | — | EP | disclosed |
| US-8466141-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2013-06-18 | — | — | US | disclosed |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| EP-2094262-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | Mazence Inc. (KR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008136642-A1 | NAPHTHOQUINONE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MAZENCE INC. (KR) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008133441-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2008-11-06 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066300-A1 | NAPHTHOQUINONE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066296-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| CN-101119726-A | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO LTD (KR) | 2008-02-06 | — | — | CN | disclosed |
| EP-1848432-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | Md Bioalpha Co., Ltd. (KR) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006088315-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041849-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MT-ND2, MT-ND1, NLN | MALT1 4475/4885STAT3 4091/4885ESR2 2000/4885 |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MT-ND2, MT-ND1, NLN | MALT1 4475/4885STAT3 4091/4885ESR2 2000/4885 |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | SLC25A20, SLC25A1, PC | MALT1 4544/4885STAT3 1006/4885ESR2 3917/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | MALT1 4688/4885STAT3 627/4885ESR2 3827/4885 |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MT-ND2, MT-ND1, NLN | MALT1 4475/4885STAT3 4091/4885ESR2 2000/4885 |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | NLN, SLC25A20, ACAD9 | MALT1 4454/4885STAT3 1312/4885ESR2 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.